Notably, IV injection of free anti-PD-L1 mAb resulted in significantly higher mortality (9/20 of tumor-bearing mice) than IV injection of anti-PD-L1-conjugated MB (2/20 of tumor-bearing mice), demonstrating that USMB improved tolerability [242]. This evidence concerns the gene CD274 and neoplasm.